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Abstract Macrolides are often used to treat group A strepto-
coccus (GAS) infections, but their resistance rates reached
high proportions worldwide. The aim of the present study
was to give an update on the characteristics and contemporary
prevalence of macrolide-resistant pharyngeal GAS in Central
Italy. A total of 592 isolates causing pharyngitis in children
were collected in the period 2012–2013. Clonality was
assessed by emm typing and pulsed-field gel electrophoresis
(PFGE) for all macrolide-resistant strains and for selected sus-
ceptible isolates. Genetic determinants of resistance were
screened by polymerase chain reaction (PCR). Forty-four
GAS were erythromycin-resistant (7.4 %). Among them,
52.3% and 50%were clindamycin- and tetracycline-resistant,
respectively. erm(B)-positive isolates (52.3 %) expressed the
constitutive cMLSB phenotype. mef(A) and its associated M
phenotype were recorded in 40.9 % of the cases. The remain-
ing erm(A)-positive isolates expressed the iMLSB phenotype.
Seventeen tetracycline-resistant isolates carried tet(M) and
five isolates carried tet(O). Twenty-five emm types were found
among all strains, with the predominance of emm types 12, 89,
1, and 4. Eleven emm types and 12 PFGE clusters character-
ized macrolide-resistant strains, with almost two-thirds be-
longing to emm12, emm4, and emm11. Macrolide-
susceptible and -resistant emm types 12, 89, 11, and 4 shared
related PFGE profiles. There was a dramatic decline in
macrolide resistance in Central Italy among pharyngeal GAS
isolates in 2012–2013 when compared to previous studies
from the same region (p<0.05), althoughmacrolide consump-
tion remained stable over the past 15 years. We observed a
decrease in the proportion of macrolide-resistant strains within
emm types commonly associated with macrolide resistance in
the past, namely emm12, 1, and 89.
Introduction
Streptococcus pyogenes, or Lancefield group A streptococcus
(GAS), is an important pathogen implicated in a wide variety
of human infections. The species is associated with both non-
invasive diseases, such as acute pharyngitis, an infection for
which it is the most common bacterial agent, and invasive
infections, such as skin and soft-tissue infections, necrotizing
fasciitis, bacteremia, sepsis, and toxic shock syndrome [1].
GAS remains sensitive to β-lactams, which is the drug
class of choice in the treatment of most streptococcal infec-
tions because of its narrow spectrum of action and its efficacy
in the prevention of post-streptococcal sequelae, such as
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rheumatic fever [1]. Macrolides have been recommended for
patients allergic toβ-lactams, and clindamycin is the preferred
antibiotic in the treatment of patients with serious soft-tissue
infections because of its ability to inhibit the production of
several streptococcal virulence factors [1]. Resistance to eryth-
romycin and related antibiotics has represented an important
cause of concern [2, 3] and is mainly associated with two
mechanisms. The first is expressed by mef genes, such as
mef(A), encoding for an efflux pump, which confers resistance
to 14- and 15-membered ring macrolides and susceptibility to
clindamycin (M phenotype) [4]. The second mechanism in-
volves erm genes, including erm(A) [subclass erm(TR)] and
erm(B), which encode methylases targeting 23S rRNA [5].
The modification is associated with a decreased binding of
all macrolides, lincosamides, and streptogramin type B to their
targets on the ribosomal RNA (MLSB phenotype), and it can
be either induced (iMLSB phenotype) or constitutive (cMLSB
phenotype). Other less common mechanisms of macrolide
resistance are associatedwith mutations in the 23S rRNAgene
sequence and/or alterations in riboproteins L4 and L22 [5].
Furthermore, an association between erythromycin resistance
and cell invasiveness has been observed [6].
The major factor thought to be influencing the prevalence
of macrolide resistance is macrolide consumption [7]. In ad-
dition, GAS clones showing emm types strongly associated
with erythromycin resistance may contribute to the overall
prevalence of macrolide resistance [8]. In this respect, Italy
has always been highly ranked in the list of countries for
macrolide resistance rates, ranging between 16 % and 36 %
in Central Italy [9–11].
The aim of the present study was to examine the prevalence
and phenotypic and genotypic characteristics of macrolide
resistance in pharyngeal GAS isolates causing pharyngitis col-
lected from children during two respiratory seasons (2012 and
2013) in Central Italy and compare our results with data pub-
lished worldwide. Antimicrobial resistance phenotypes and
genotypes were defined; the overall genotypes of strains were




GAS strains were collected from symptomatic individuals
with pharyngotonsillitis from three different hospitals located
in Central Italy during the respiratory season (January to June)
in the years 2012 and 2013. One center is the largest referral
pediatric hospital situated in Rome, while the others are gen-
eral hospitals placed in Macerata and Perugia (Central Italy).
All non-duplicate pharyngeal GAS clinical isolates included
in the study were identified by colony morphology, β-
hemolysis on blood agar, latex agglutination test
(Streptococcal Grouping Kit, Oxoid, Basingstoke, UK), and
susceptibility to bacitracin disks (10 U, Oxoid, Basingstoke,
UK).
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by disk diffusion
on Mueller–Hinton agar supplemented with 5 % defibrinated
horse blood and 20 mg/L β-NAD, according to the guidelines
and interpretative criteria of the European Committee on
Antimicrobial Susceptibility Testing (EUCAST). The follow-
ing antibiotic disks were included (Oxoid, Basingstoke, UK):
penicillin G, erythromycin, clindamycin, tetracycline,
norfloxacin, rifampicin, quinupristin/dalfopristin, and linezo-
lid. Norfloxacin disks were used to screen for generic fluoro-
quinolone resistance. Isolates categorized as norfloxacin-
suscep t ib l e were cons ide red suscep t ib l e to a l l
fluoroquinolones. The double-disk diffusion test was used to
assign the strain to either the constitutive macrolide–
lincosamide–streptogramin B (cMLSB), the inducible MLSB
(iMLSB), or the M phenotype [10].
Detection of genetic determinants of antimicrobial
resistance
Total bacterial DNA was extracted by the GenElute™
Bacterial Genomic DNA Kit (Sigma-Aldrich, St. Louis,
MO, USA). Erythromycin-resistant isolates were studied for
the presence of the macrolide resistance genes erm(A) [sub-
class erm(TR)], erm(B), and mef(A) by polymerase chain re-
action (PCR) [12]. Erythromycin-resistant GAS being resis-
tant also to tetracycline were analyzed by PCR to determine
the presence of the resistance genes tet(M) and tet(O) [13].
emm typing
Isolates were emm typed according to protocols and recom-
mendations by the StreptococcusLaboratory at the Centers for
Disease Control and Prevention (CDC, Atlanta, GA, USA).
Assignment of the emm type is achieved by the comparison of
the query sequence with the emm type reference database. The
analysis considers 90 bases encoding the N-terminal part of
the mature M protein.
PFGE macrorestriction analysis
Total DNA from all erythromycin-resistant and a selected sub-
group of erythromycin-susceptible isolates was extracted and
digestedwith 20U of SmaI (Fermentas, Vilnius, Lithuania), as
previously described [12]. As for DNA of isolates not digested
with SmaI, the restriction enzyme Cfr9I, an isoschizomer of
SmaI, was used, as previously described [14]. DNA bands
1798 Eur J Clin Microbiol Infect Dis (2015) 34:1797–1802
were resolved and interpreted according to previously report-
ed criteria [15]. Briefly, isolates with identical profiles were
assigned to the same PFGE type; isolates with profiles differ-
ing by 1 to 6 bands were assigned to different subtypes within
the same PFGE type; isolates with profiles showing more than
6 bands of difference were considered unrelated.
Statistical analysis
Statistical analysis was performed by Centurion XV software
(STATGRAPHICS). Comparison of partitions and pairwise
agreement measures were done according to Silva-Costa
et al. [8] and expressed as adjusted Wallace coefficients.
Results
Antibiotic resistance rates, phenotypes, and genotypes
A total of 592 GAS isolates were collected from children with
pharyngitis during the periods January–June 2012 and 2013.
Patients were aged between 2 and 13 years (mean=6.7 years,
standard deviation =2.7 years), and 56 % were males. A total
of 44 GASwere erythromycin-resistant, with an overall rate of
erythromycin resistance of 7.4 %. Over the 2-year period un-
der investigation, a decreasing trend of erythromycin resis-
tance was observed (28/293 isolates, 9.6 %, in 2012 vs. 16/
299, 5.4 %, in 2013; p=0.06).
All resistant GAS were uniformly susceptible to all antibi-
otics tested except for clindamycin (52.3 %) and tetracycline
(50 %). All macrolide-resistant isolates with the M phenotype
carried mef(A), all three isolates presenting the iMLSB pheno-
type carried erm(A), and all erm(B)-positive isolates exhibited
the cMLSB phenotype (Table 1). No isolates simultaneously
carried more than one resistance determinant. The macrolide
resistance cMLSB/erm(B) phenotype/genotype was the most
frequent (52.3 %), followed by M/mef(A) (40.9 %) and
iMLSB/erm(A) (6.8 %) (Table 1). The prevalence of
macrolide resistance phenotypes/genotypes varied slightly
during the study period, with a decrement of M/mef(A) from
2012 to 2013, the appearance of iMLSB/erm(A) during 2013,
while cMLSB/erm(B) remained quite constant and was the
most prevalent over time (Table 1).
Clonal characterization
Among all GAS isolates collected during the 2-year survey, 25
different emm types were identified. emm types 12, 89, 1, and
4 were the most prevalent, accounting for about 50 % of all
isolates. We found that erythromycin-resistant isolates repre-
sented only 13 %, 2.9 %, 4.6 %, and 16.7 % of emm type 12,
89, 1, and 4 subgroups, respectively. The clonal characteriza-
tion of erythromycin-resistant strains is illustrated in Table 2,
showing 11 different emm types , eight of which represented
by two or more erythromycin-resistant strains. The predomi-
nant emm types were emm12 and 4 (11 strains each, 25 %),
followed by emm11 (seven isolates), which were recovered in
both study years and accounted for 66 % of all erythromycin-
resistant strains (Table 2). As indicated in Table 2, the relative
frequencies of emm types encountered during the two study
years differed slightly, although not significantly as per
Fisher’s exact test analysis performed on the three most prev-
alent emm types. Five emm types were found during both
years, while six were single year-associated but represented
the less frequent emm types among erythromycin-resistant
isolates (Table 2). In order to assess seasonal variation in
macrolide-resistant emm types distribution, we divided each
year into two seasonal periods (January–March and April–
June), but no significant differences were found in the preva-
lence of each emm type (data not shown).
Tetracycline-resistant isolates that carried erm(B) and
tet(M) belonged to five different emm types, the majority of
isolates belonging to emm types 12 and 11 (seven isolates
each). Three mef(A)- and tet(O)-positive isolates were emm
type 2, and the two isolates harboring erm(A) and tet(O) were
emm type 77 (Table 2).
PFGE analysis was able to discriminate 12 different types
(Table 2). An overall concordance was found between emm
types and PFGE types (adjusted Wallace coefficient: 0.852;
95 % confidence interval: 0.714–0.991), with each emm type
being associatedwith a specific and unique PFGE type, except
for the emm type 4 group, wherein two different PFGE types
were found (Table 2). Also, emm type 12, which was the most
heterogeneous in terms of macrolide resistance determinants,
was associated with a single PFGE type (type 3) (Table 2). It
was possible to recognize three major clones, which were
represented by more than three isolates and defined by the
association of emm type, PFGE type, and resistance gene
Table 1 Annual and total
prevalence of macrolide
resistance genes and phenotypes
within the 44 macrolide-resistant
group A streptococcus (GAS)
Macrolide resistance gene/phenotype No. of resistant strains (%)
2012 2013 2012+2013
mef(A)/M 14 (50 %) 4 (25 %) 18 (40.9 %)
erm(A)/iMLSB 0 3 (18.75 %) 3 (6.8 %)
erm(B)/cMLSB 14 (50 %) 9 (56.25 %) 23 (52.3 %)
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profile (Table 2). Macrolide-sensitive isolates belonging to
emm types 4, 11, 12, and 89 were randomly chosen and ge-
notyped by PFGE (three isolates for each emm type). Their
profiles were related to those of the most prevalent macrolide-
resistant strains of the corresponding emm types, namely
PFGE type 1 for emm type 4, PFGE type 3 for emm type 12,
PFGE type 4 for emm type 11, and PFGE type 9 for emm type
89 (data not shown).
Discussion
The macrolide resistance rates vary considerably among GAS
strains from different countries and over time between<3% to
>26 % [2, 16–20]. In Europe from 2005 onwards, while in
some regions macrolide resistance rates continued to remain
high with an increasing trend, such as Greece [20], in others,
such as Spain, Portugal, France, and Germany, a significant
decrease of macrolide resistance rates was reported [14,
21–23].
In Italy, based on regional studies mainly, macrolide resis-
tance rates steadily increased from 9 % in 1992 to 53 % in
1997 [24]. Over the period 2000–2009, the rates continued to
remain high in Central Italy, varying between 16 % and 36 %
[10, 11]. In those years, Italy was among the regions with the
highest levels of erythromycin resistance in Europe.
According to the present study, we witnessed, for the first
time, a decline in macrolide resistance rates in Central Italy,
among GAS isolates over the period 2012–2013, down to 7.4 %.
erm(B) was the predominant macrolide resistance gene
found, followed by mef(A). erm(B) was responsible for the
increase in macrolide resistance rates observed in Italy during
the period 1992–1997 and remained prevalent between 2000
and 2003 [10, 24]. In the present study, the erm(A) gene was
rarely found, as also reported in Belgium [25].
In this study, among erythromycin-resistant isolates, emm
types 12, 4, and 11 predominated, accounting for 66 % of all
resistant strains. In Italy, while emm types 12 and 4 were the
most prevalent types among erythromycin-resistant isolates in
previous studies, emm11 was only rarely found, even among
susceptible strains [10, 26]. Associations between emm types
and macrolide resistance genes resulted to be the same as to
those found previously, with only rare exceptions, thus sug-
gesting that, in Italy, few successful clones are associated with
macrolide resistance [9, 10, 26]. With only one exception,
represented by emm type 4 with two different PFGE types,
each emm type was specifically associated with a distinct
PFGE type. The most prevalent emm types found among our
GAS strains represent also those types frequently detected in
different geographical areas [2, 20–22]. An mef(A)-positive/
emm4 clone has been frequently found associated with
macrolide resistance in GAS [8, 20, 22], as well as an
erm(B)-positive/emm11 clone that seemed to increase in prev-
alence in some countries [14, 21, 22, 27]. The finding of
specific associations between emm type and macrolide resis-
tance genotype and the fact that some emm types are never or
rarely found in resistant isolates are suggestive of the limited
transfer of macrolide resistance determinants within GAS.
Nevertheless, rare emm type/resistance gene associations have
been found in our study. It is the case of the second most
prevalent detected clone, the erm(B)-positive/emm12/PFGE
3, whereas emm12 isolates resistant to macrolides have been
Table 2 Cross tabulation of emm types, pulsed-field gel electrophoresis (PFGE) clustering, and genotypes/phenotypes of resistance for the 44
macrolide-resistant group A streptococcus (GAS) strains isolated in Italy (2012–2013)
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All 2012 2013 erm(A) erm(B) mef(A)
4 11.2 11 (25) 9 (25) 2 (12.5) 1 (9); 2 (2) 0 0 11 none Ery (11)
12 13.0 11 (25) 7 (32.1) 4 (25) 3 (11) 1 7 3 tet(M) (7) Ery,Cli,Tet (7); Ery (4)
11 1.4 7 (15.9) 4 (14.3) 3 (18.8) 4 (7) 0 7 0 tet(M) (7) Ery,Cli,Tet (7)
1 11.2 3 (6.8) 3 (10.7) 0 5 (3) 0 3 0 none Ery,Cli (3)
2 1.2 3 (6.8) 2 (7.1) 1 (6.3) 6 (3) 0 0 3 tet(O) (3) Ery,Tet (3)
44 5.1 2 (4.5) 0 2 (12.5) 7 (2) 0 2 0 tet(M) (2) Ery,Cli,Tet (2)
77 0.3 2 (4.5) 0 2 (12.5) 8 (2) 2 0 0 tet(O) (2) Ery,Tet (2)
89 11.8 2 (4.5) 1 (3.6) 1 (6.3) 9 (2) 0 2 0 tet(M) (1) Ery,Cli,Tet (1); Ery,Cli (1)
18 3.6 1 (2.3) 1 (3.6) 10 (1) 0 1 0 none Ery,Cli (1)
75 2.2 1 (2.3) 1 (3.6) 11 (1) 0 0 1 none Ery (1)
132 0.2 1 (2.3) 0 1 (6.3) 12 (1) 0 1 0 tet(M) (1)b Ery,Cli (1)b
a All isolates positive to mef(A) but the emm2 and one of the emm12 isolates were genotyped by PFGE using Cfr9I restriction enzyme, because their
genomic DNAwas not digested by SmaI
b Isolate found to be tet(M)-positive but tetracycline-susceptible
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previously found associated with mef(A) [2, 21, 25], and the
case of three emm1 isolates with erm(B), whereas emm1-re-
sistant isolates are generally mef(A)-positive [22, 27]. The
uncommon emm types/macrolide resistance associations ob-
served in this study could reflect circulation of different clonal
lineages in this geographic area.
The finding of 17 out of 22 (77.3 %) erythromycin- and
tetracycline-resistant isolates that carried both erm(B) and
tet(M) could suggest that these isolates may carry conjugative
transposons belonging to the Tn916 family, such as Tn3872,
Tn6002, Tn6003, Tn1545, and Tn2010, where erm(B) and
tet(M) are genetically associated [13]. These erm(B)/tet(M)
isolates belonged to six different emm types, the predominant
being emm types 12 and 11 (seven isolates each). While the
association between emm type 11 and erm(B)/tet(M)-mediat-
ed co-resistance has already been reported [27], emm12 iso-
lates carrying both erm(B) and tet(M) are very rare, due to the
unusual association of this emm type with erm(B), as stated
above. Three emm2 isolates hadmef(A) and tet(O), suggesting
that they may carry the transferable chimeric prophage
Φm46.1 [28]. The two erythromycin- and tetracycline-
resistant isolates of emm type 77 harbored erm(A) and tet(O).
High-level macrolide consumption, especially long-acting
macrolides, have been directly associated with an increase of
macrolide resistance, due to the antibiotic selective pressure,
which could favor the spread of specific macrolide-resistant
GAS clones, with changes in macrolide resistance rates and
genotypes [19]. In some countries, reduction in macrolide
consumption proved to be an important factor responsible
for the decline in macrolide resistance rates [22, 23, 25]. In
Italy, macrolide consumption remained relatively stable dur-
ing the last 15 years (1999–2013) [29], although available data
refer to the general population and not to the pediatric group
only. Also, the consumption of tetracyclines, which have been
associated with the increase of macrolide resistance, remained
stable [29]. Althoughwe do not have information on antibiotic
usage in the patients of this study, the observed decline in
macrolide resistance rates seems to not correlate to general
macrolide consumption. A recent study from Slovenia indi-
cated even the opposite; that is, a boost in resistance rates
among non-invasive GAS, despite a decrease in macrolide
use [30]. Thus, besides the presumed association with antibi-
otic use, other underlying mechanisms influencing the devel-
opment and spread of antibiotic-resistant GAS isolates are to
be considered, such as natural fluctuations in the prevalence of
resistant clones and low fitness costs of some erythromycin-
resistant clones [25].We found that the major emm types in the
overall GAS pharyngeal population circulating in Italy during
2012–2013 were the same as those reported in previous Italian
studies, specifically emm types 4, 12, and 89, although with
differences in their relative frequencies [10, 26]. Some of the
most frequent emm types were also the most prevalent among
erythromycin-resistant strains. PFGE was not able to
differentiate resistant and susceptible isolates belonging to
the same emm type, and this observation seems to indicate
that the decrease of macrolide resistance would not be due to
a decrement of specific GASmacrolide-resistant clones within
a given emm type.
This study documents a decline in macrolide resistance
rates in Italy, where macrolide resistance has been document-
ed to be high in the past, and it provides useful comparative
data for future epidemiological studies across erythromycin-
resistant GAS populations.
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